MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

MDT

86.08

+0.56%↑

A

121.65

+2.99%↑

VEEV

167.9

+0.35%↑

HQY

85.93

+1.81%↑

NEOG

9.5

+2.81%↑

Search

TransMedics Group Inc

Închisă

SectorSănătate

115.83 5.79

Rezumat

Modificarea prețului

24h

Curent

Minim

113.95

Maxim

120.5

Indicatori cheie

By Trading Economics

Venit

81M

105M

Vânzări

17M

161M

P/E

Medie Sector

23.277

63.808

Marjă de profit

65.551

Angajați

898

EBITDA

-916K

32M

Recomandări

By TipRanks

Recomandări

Cumpărare

Prognoză pe 12 luni

+33.58% upside

Dividende

By Dow Jones

Următoarele câștiguri

7 mai 2026

Statistici piață

By TradingEconomics

Capitalizare de piață

-686M

3.9B

Deschiderea anterioară

110.04

Închiderea anterioară

115.83

Sentimentul știrilor

By Acuity

25%

75%

73 / 348 Clasament în Healthcare

Scor tehnic

By Trading Central

Încredere

Weak Bearish Evidence

TransMedics Group Inc Grafic

Performanțele din trecut nu reprezintă un indicator fiabil al rezultatelor viitoare.

Știri relevante

4 aug. 2025, 19:15 UTC

Principalele dinamici ale pieței

TransMedics Group Shares Rise on FDA Approval for Clinical Trial

Comparație

Modificare preț

TransMedics Group Inc Așteptări

Obiectiv de preț

By TipRanks

33.58% sus

Prognoză pe 12 luni

Medie 155.1 USD  33.58%

Maxim 190 USD

Minim 118 USD

În baza a 11 analiști de pe Wall Street care oferă obiective de preț pe 12 luni pentruTransMedics Group Inc - Dist în ultimele 3 luni.

Consens privind evaluarea

By TipRanks

Cumpărare

11 ratings

8

Cumpărare

3

Păstrare

0

Vânzare

Scor tehnic

By Trading Central

92.43 / 94.18Suport & Rezistență

Termen scurt

Weak Bearish Evidence

Termen mediu

Bullish Evidence

Termen lung

Weak Bullish Evidence

Sentiment

By Acuity

73 / 348 Clasament în Sănătate

Sentimentul știrilor

Evidențe foarte puternice de creștere

Volatilitate

Sub medie

Volumul știrilor (RCV)

Sub medie

Date financiare

Cheltuieli de vânzare și administrare

Cheltuieli de exploatare

Profit pre-impozitare

Vânzări

Costul vânzărilor

Profit brut din vânzări

Cheltuieli cu dobânzile pe datorie

EBITDA

Profit operațional

$

Despre TransMedics Group Inc

TransMedics Group, Inc., a commercial-stage medical technology company, engages in transforming organ transplant therapy for end-stage organ failure patients in the United States and internationally. The company offers Organ Care System (OCS), a portable organ perfusion, optimization, and monitoring system that utilizes its proprietary and customized technology to replicate near-physiologic conditions for donor organs outside of the human body. Its OCS includes OCS LUNG for the preservation of standard criteria donor lungs for double-lung transplantation; OCS Heart, a technology for preservation of DBD donor hearts deemed unsuitable due to limitations of cold storage and for ex vivo reanimation, functional monitoring, and beating-heart preservation of donation-after-circulatory-death hearts; and OCS Liver for the preservation of DBD and DCD of donor livers. The company also developed national OCS program, a turnkey solution for outsourced organ retrieval; and provides OCS organ management and logistics services, including aviation and ground transportation, and other coordination activity. The company was founded in 1998 and is headquartered in Andover, Massachusetts.
help-icon Live chat